SynAct Pharma secures patent for resomelagon in combination with MTX
The United States Patent and Trademark Office has issued a Notice of Allowance for SynAct Pharma’s patent application covering the use of resomelagon in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis. This indicates that the patent office intends to grant the patent, further strengthening the company’s patent portfolio.
SynAct Pharma’s lead candidate, resomelagon (AP1189), is currently undergoing evaluation as an add-on to methotrexate (MTX) – a widely used first-line treatment for rheumatoid arthritis (RA). The company’s phase IIb clinical trial in RA is underway in both the US and EU, with patient enrolment expected to be completed in Q4 2025.
Strengthened patent protection
The intellectual property rights and exclusivity for resomelagon in combination with MTX have recently been further reinforced. On March 23, SynAct Pharma announced that a patent covering this combination therapy will be granted by the United States Patent and Trademark Office (USPTO) upon completion of all formalities. The patent will ensure protection at least until 2040.
This new patent complements a recently granted U.S. patent protecting the crystalline form of resomelagon used in clinical practice. Together, these patents will reinforce SynAct’s growing patent portfolio, which includes multiple granted patents and pending applications across key international markets.
Jeppe Øvlesen, CEO of SynAct Pharma, emphasises the strategic importance of a strong patent foundation:
– A strong patent portfolio, which ensures exclusivity in key markets like the US, potentially has a very big value for us and our potential partners. A patent on the combination treatment of RA with resomelagon and one of the most widely used drugs for RA, such as MTX, is certainly consolidating our position.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
